Homogeneous, bioluminescent proteasome assays

Methods in Molecular Biology

Volumn 414, Issue , 2007, Pages 163-181

  O'Brien, Martha A ^a   Moravec, Richard A ^a   Riss, Terry L ^a   Bulleit, Robert F ^a  

^a NONE

Author keywords

20S proteasome; 20S proteasome assay; Aminoluciferin; Bioluminescence; Bioluminescent protease assay; Luciferase

Indexed keywords

EID: 37849050529     PISSN: 10643745     EISSN: None     Source Type: Book Series    
DOI: 10.1385/1-59745-339-0:163     Document Type: Article

References (29)

1. Adams, J., Palombella, V.J., Sausville, E.A., Johnson, J., et al. (1999) Proteasome inhibitors: a novel class of potent and effective antitumor agents. Cancer Res. 59, 2615-2622.
2. Adams, J. (2002) Development of the proteasome inhibitor PS-341. Oncologist 7, 9-16.
3. Voorhees, P.M., Dees, E.G., O'Neil, B., and Orlowski, R.Z. (2003) The proteasome as a target for cancer therapy. Clin. Cancer Res. 9, 6316-6325.
4. Burger, A.M., and Seth, A.K. (2004) The ubiquitin-mediated protein degradation pathway in cancer: therapeutic implications. Eur. J. Cancer 4, 2217-2229.
5. Gu, Z., Nakamura, D., Yao, D., Shi, Z.-Q., and Upton, S.A. (2005) Nitrosative and oxidative stress links dysfunctional ubiquitination to Parkinson's disease. Cell Death Diff 12, 1202-1204.
6. Baumeister, W., Walz, J., Zühl, F., and Seemüller, E. (1998) The proteasome: paradigm of a self-compartmentalizing protease. Cell 92, 367-380.
7. Wolf, D.H., and Hilt, W. (2004) The proteasome: a proteolytic nanomachine of cell regulation and waste disposal. Biochem. Biophys. Acta 1695, 19-31.
8. Glickman, M.H., and Ciechanover, A, (2002) The ubiquitin-proteasome proteolytic pathway: destruction for the sake of construction. Physiol. Rev. 82, 373-428.
9. Rajkumar, S.V., Richardson, P.G., Hideshima, T., and Anderson, K.C. (2005) Proteasome inhibition as a novel therapeutic target in human cancer. J. Clin. Oncol, 23, 630-639.
10. Nussbaum, A.K., Dick, T.P., Keilholz, W., Schirle, M., et al. (1998) Cleavage motifs of the yeast 2OS proteasome subunits deduced from digest of enolase I. Proc. Natl. Acad. Sci. U. S. A. 95, 12504-12509.
11. Rechsteiner, M., and Hill, C.P. (2005) Mobilizing the proteolytic machine: cell biological roles of proteasome activators and inhibitors. Trends Cell Biol. 15, 27-33.
12. Kisselev, A.F., Kaganovich, D., and Goldberg A.L. (2002) Binding of hydrophobic peptides to several non-catalytic sites promotes peptide hydrolysis by all active sites of 20S proteasomes. J. Biol. Chem. 277, 22260-22270.
13. Kisselev, A.F., Garcia-Calvo, M., Overkleeft, H.S., Peterson, E., et al. (2003) The caspase-like sites of proteasomes, their substrate specificity, new inhibitors and substrates, and allosteric interactions with the trypsin-like sites. J. Biol. Chem, 278, 35869-35877.
14. Ciechanover, A. (2005) Intracellular protein degradation: from, a vague idea thru the lysosome and the ubiquitin-proteasome system and onto human diseases and drug targeting. Cell Death Diff. 12, 1178-1190.
15. Chauhan, D., Hideshima, T., and Anderson, K.C. (2005) Proteasome inhibition in multiple myeloma: therapeutic implication. Ann. Rev. Pharmacol. Toxicol. 45, 465-476.
16. Chauhan, D., Catley, L., Li, G., Podar, K., et al. (2005) A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from Bortezomib. Cancer Cell 8, 407-419.
17. Richardson, P.G., Barlogie, B., Berenson, J., Singhal, S., et al. (2003) Phase 2 study of bortezomib in relapsed, refractory myeloma. N. Engl. J. Med. 348, 2609-2617.
18. Papandreou, C.N., and Logothetis, C.J. (2004) Bortezomib as a potential treatment for prostate cancer. Cancer Res. 64, 5036-5043.
19. Leytus, S.P., Melhado, L.L., and Mangel, W.F. (1983) Rhodamine-based compounds as fluorogenic substrates for serine proteinases. Biochem, J. 209, 299-307.
20. Liu, J., Bhalgat, M., Zhang, C., Diwu, Z., Hoyland, B., and Klaubert, D.H. (1999) Fluorescent molecular probes V: a sensitive caspase-3 substrate for fluorometric assays. Bioorg. Med. Chem. Lett. 9, 3231-3236.
21. Grant, S.K., Sklar, J.G., and Cummings, R.T. (2002) Development of novel assays for proteolytic enzymes using rhodamine-based fluorogenic substrates. J. Biomol. Screen. 7, 531-540.
22. O'Brien, M.A., Daily, W.J., Hesseiberth, P.E., Moravec, R.A., et al. (2005). Homogeneous, bioluminescent protease assays: caspase-3 as a model. J. Biomol. Screen, 10, 137-148.
23. Lightcap, E.S., Mccormack, T.A., Pien, C.S., Chau, V., et al. (2000) Proteasome inhibition measurements: clinical application. Clin. Chem. 46, 673-683.
24. Fenteany, G., Standaert, R.F., Lane, W.S., Choi, S., et al. (1995) Inhibition of proteasome activities and subunit-specific amino-terminal threonine modification by lactacystin. Science 268, 726-731.
25. Dick, L., Cruikshank, A., Grenier, L., Melandri, F.D., et al. (1996) Mechanistic studies on the inactivation of the proteasome by lactacystin: a central role for clasto-lactacystin β-lactone. J. Biol. Chem. 271, 7273-7276.
26. Dick, L., Cruikshank, A., Destree, A.T., Grenier, L., et al. (1997) Mechanistic studies on the inactivation of the proteasome by lactacystin in cultured cells. J. Biol. Chem. 272, 182-188.
27. Meng, L., Mohan, R.L., Kwok, B.H.B., Elofsson, M., Sin, N., and Crews, C.M. (1999) Epoxomicin, a potent and selective proteasome inhibitor, exhibits in vivo anti-inflammatory activity. Proc. Natl. Acad. Sci. U. S. A. 96, 10403-10408.
28. Corey, E.J., and Li, W.-D.Z. (1999) Total synthesis and biological activity of lactacystin, omuralike and analogs. Chem, Pharm, Bull, 47, 1-10.
29. Wojcik, C., and Napoli, M.D. (2004) Ubiquitin-proteasome system and proteasome inhibition: new strategies in stroke therapy. Stroke 35, 1506-1518.